Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - ARQULE INC | ex99-1.htm |
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 24, 2013
ARQULE, INC.
(Exact Name of Issuer as Specified in Charter)
| Delaware | 000-21429 | 04-3221586 | ||
| (State or other jurisdiction | (Commission File Number) | (I.R.S. Employer | ||
| of incorporation) | Identification No.) |
| 19 Presidential Way | ||||
| Woburn, MA | ||||
| (Address of principal executive offices) | ||||
|
01801
|
||||
|
(Zip code)
|
||||
| (781) 994-0300 |
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
|
o
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
o
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Section 2 – Financial Information
Item 2.02 Results of Operations and Financial Condition.
On July 30, 2013 ArQule, Inc. (the “Registrant” or the “Company”) issued a press release announcing (i) its results of operations for the fiscal quarter ended June 30, 2013 and (ii) a focused reduction in its workforce. The press release is furnished as Exhibit 99.1 hereto and incorporated herein by reference.
Item 2.05 Costs Associated With Exit Or Disposal Activities.
On July 24, 2013, the Company approved, effective as of July 29, 2013, a focused reduction in the Company’s workforce of approximately 25 positions resulting in a remaining workforce of approximately 67 employees. This action is intended to align human and financial resources with the Company’s primary focus on clinical-stage development, while retaining its core discovery capabilities. The Company estimates that the costs associated with this action will be comprised principally of severance payments of approximately $525,000 and benefits continuation costs of approximately $100,000, all of which are expected to be paid by December 31, 2013. In addition, in the third quarter of 2013, the Company expects to incur non-cash charges of approximately $150,000 related to the modification of employee stock options.
As a result, the Company anticipates that its cash, cash equivalents and marketable securities on hand at June 30, 2013, financial support from its collaboration agreements and savings from the workforce reduction referenced above will be sufficient to finance the Company’s working capital and capital requirements into 2016, with no impact on current financial guidance for 2013.
Forward-Looking Statements
The
statements above regarding the Company’s estimates of the amount and timing of charges related to the workforce
reduction are forward-looking statements and are subject to a number of assumptions. Such forward-looking
statements are based upon management’s current expectations and are subject to known and unknown risks and
uncertainties that could cause actual results, events or developments to be materially different from those indicated in such forward-looking
statements. The Company expressly disclaims any intent or obligation to update these forward-looking statements, except as
required by law.
Section 9 – Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit 99.1 Text of press release dated July 30, 2013 announcing results of operations and a reduction in workforce.
| 2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ARQULE,
INC. (Registrant) |
||
| /s/ Peter S. Lawrence | ||
| Peter S. Lawrence | ||
|
President and Chief Operating Officer
|
July 30, 2013
| 3 |